- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03297346
Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY-HEART)
Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project
Breast cancer (BC) radiotherapy leads to coincidental radiation of the heart, resulting in increased risk of a variety of heart diseases. Identifying BC patients with the highest risk of radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention. Little has been done on the relationship between dose distribution to different anatomical cardiac structures during radiotherapy and early cardiovascular changes that may lead to cardiac complications.
In the framework of the European project MEDIRAD, the EARLY-HEART multicenter prospective cohort was launched in August 2017, involving 5 investigating centers from France, Netherlands, Germany, Spain and Portugal. With 250 BC patients prospectively followed for 2 years, the main objective is to identify and validate the most important cardiac imaging (echocardiography, computed tomography coronary angiography, cardiac magnetic resonance imaging) and circulating biomarkers of radiation-induced cardiovascular changes arising in the first 2 years after BC radiotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
EARLY-HEART is a multicentre prospective cohort study that will include 250 female primary breast cancer cases aged 40-75 years treated with postoperative radiotherapy (RT) alone after breast-conserving surgery using modern planning-CT based RT technologies and followed for 2 years after RT in one of the 5 participating hospitals. In addition to the standard follow-up, patients will need to give repeated blood samples and will undergo repeated cardiac imaging:
- Functional and anatomical cardiac imaging biomarkers will be based on automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed Tomography Coronary Angiography (CT) and cardiac magnetic resonance imaging (MRI).
- Circulating biomarkers (BLOOD) will be based on a panel of multiple classical or novel blood-based biomarkers.
Imaging and circulating biomarkers measurements will be assessed at baseline before RT (ECHO, CT, MRI, BLOOD); at the end of RT (BLOOD); 6 months after RT (ECHO, MRI, BLOOD) and 24 months after RT (ECHO, CT, MRI, BLOOD).
Changes in functional and anatomical cardiac imaging and circulating biomarkers between unexposed status before RT and exposed status after RT at different time points will be first analysed to evaluate the effects of RT on the heart.
All relevant DICOM-data (including planning-CT scans and the ECHO, MRI and CT) will be centralized to the MEDIRAD-ENACT database managed by University of Groningen for automated segmentation of all cardiac substructures (including coronary arteries) to ensure uniformity of the segmentation procedure between centres. The RT planning CTs will be used to generate dose volume histograms and 3D dose maps of the heart and cardiac substructures in order to correlate the localization of any cardiovascular change with the anatomical dose distribution.
In the presence of a cardiac outcome, a multimetric Normal Tissue Complication Probability (NTCP) individual risk model will be constructed and an integrative clinical-biologic risk score will be developed for individual risk prediction.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sophie Jacob, PhD
- Phone Number: +33561145608
- Email: sophie.jacob@irsn.fr
Study Locations
-
-
-
Toulouse, France
- IRSN - Clinique Pasteur
-
-
-
-
-
Munich, Germany
- Klinikum rechts der Isar der Technischen Universität München
-
-
-
-
-
Groningen, Netherlands
- Academisch Ziekenhuis Groningen
-
-
-
-
-
Lisbon, Portugal
- Associação para Investigação e Desenvolvimento da Faculdade de Medicina
-
-
-
-
-
Girona, Spain
- Institut Catala d'Oncologia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female unilateral breast cancer patients
- Treated with primary breast conserving surgery for stage I-III invasive adenocarcinoma of the breast or ductal carcinoma in situ (DCIS)
- Age between 40-75 years at time of start radiotherapy
- World Health Organisation (WHO) performance status 0-1
- Planned for radiotherapy alone to the breast with or without the lymph node areas
- Radiotherapy based on planning-CT scan using either three dimensional conformal radiation therapy (3D-CRT), Intensity-modulated radiotherapy (IMRT), or Volumetric Arc Therapy (VMAT/RapidArc)
- Written Informed consent
Exclusion Criteria:
- Male breast cancer patients
- Neoadjuvant or adjuvant chemotherapy
- M1 disease (metastatic breast cancer)
- Medical history of coronary artery disease and/or myocardial infarction and/or atrial fibrillation
- Previous thoracic or mediastinal radiation
- Contraindications to injection of iodinated contrast such as allergy or renal failure
- Pregnancy or lactation
- Atrial fibrillation detected during electrocardiogram before radiotherapy
- Abnormal echocardiography before radiotherapy defined as: Left Ventricular Ejection Fraction<50%; longitudinal strain ≤ -16%; longitudinal strain rate <-1%, and/or abnormal wall motion
- Presence of myocardial infarction detected during MRI before radiotherapy
- CT or MRI results before radiotherapy requiring revascularisation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Breast cancer patients treated with RT
Cardiac imaging and circulating biomarkers measurements to evaluate:
|
Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with decreased myocardial function assessed by echocardiography
Time Frame: 2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Number of patients with an increased of at least 2.5% in the Global Longitudinal Strain (GLS) between baseline and 2 years after radiotherapy
|
2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in myocardial function measurements assessed by echocardiography
Time Frame: 6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Increase of the segmental strain measurements (unit of measures:%)
|
6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Anatomical changes in coronary arteries assessed by cardiac CT
Time Frame: 2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Increase of the number of coronary segments containing any plaque or increase of the calcium score
|
2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Myocardial tissue abnormalities assessed by cardiac MRI
Time Frame: 6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Increase of the native mean myocardial T1 mapping value
|
6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Changes in circulating biomarkers measurements
Time Frame: at the end of radiotherapy (through radiotherapy completion, an average of 5 weeks after starting date of radiotherapy), 6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Significant increase or decrease in the following biomarkers: classical biomarkers of cardiac injury (C-reactive protein, Troponin I, Troponin T, B-type natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-Pro BNP), beta2-Microglobulin, Galectin 3); Inflammatory cytokines; biomarkers of endothelial activation and dysfunction; Microparticles; MicroRNAs; circulating DNA methylation |
at the end of radiotherapy (through radiotherapy completion, an average of 5 weeks after starting date of radiotherapy), 6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Sophie Jacob, PhD, Institut de Radioprotection et de Surete Nucleaire
Publications and helpful links
General Publications
- Locquet M, Spoor D, Crijns A, van der Harst P, Eraso A, Guedea F, Fiuza M, Santos SCR, Combs S, Borm K, Mousseaux E, Gencer U, Frija G, Cardis E, Langendijk H, Jacob S. Subclinical Left Ventricular Dysfunction Detected by Speckle-Tracking Echocardiography in Breast Cancer Patients Treated With Radiation Therapy: A Six-Month Follow-Up Analysis (MEDIRAD EARLY-HEART study). Front Oncol. 2022 Jun 28;12:883679. doi: 10.3389/fonc.2022.883679. eCollection 2022.
- Walker V, Crijns A, Langendijk J, Spoor D, Vliegenthart R, Combs SE, Mayinger M, Eraso A, Guedea F, Fiuza M, Constantino S, Tamarat R, Laurier D, Ferrieres J, Mousseaux E, Cardis E, Jacob S. Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer: Protocol for a European Multicenter Prospective Cohort Study (MEDIRAD EARLY HEART Study). JMIR Res Protoc. 2018 Oct 1;7(10):e178. doi: 10.2196/resprot.9906.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEDIRAD EARLY-HEART_1.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Eli Lilly and CompanyActive, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial CancerUnited States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
Clinical Trials on Cardiac imaging and circulating biomarkers
-
Imperial College LondonActive, not recruiting
-
University Hospital, CaenInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Kidney Injury | Renal TransplantationFrance
-
Guizhou Medical UniversityNot yet recruitingNon-small Cell Lung Cancer
-
Abramson Cancer Center at Penn MedicineRecruiting
-
Memorial Ankara HospitalUnknownHeart Diseases | Stroke | Thrombosis | Atrial Fibrillation | Genetic Predisposition
-
Sophie JACOBInstitut National de la Santé Et de la Recherche Médicale, France; Clinique... and other collaboratorsCompletedBreast Cancer | Cardiac ToxicityFrance
-
Liverpool University Hospitals NHS Foundation TrustNot yet recruitingMajor Adverse Cardiac Events | Haemodialysis Complication
-
Hospital Universitario Virgen de la ArrixacaJuan Cinca Cuscullola; Pablo García Pavía; Manuel Martinez Selles; Antoni Bayés... and other collaboratorsCompletedHeart Failure | Preserved Left Ventricular Ejection FractionSpain
-
Children's Hospital Medical Center, CincinnatiThe Leona M. and Harry B. Helmsley Charitable TrustActive, not recruiting